Cancer of StomachOesophageal CancerGastric CancerGastric AdenocarcinomaGI CancerGISTNeuroendocrine TumorsGastric NeoplasmEsophageal Neoplasms
Study summary
To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* UGI neoplastic lesions \> 10mm
* Lesions for ESD limited to the mucosal and/or submucosal layer OR
* Lesions for EFTR limited to the muscularis propria layer OR
* Lesions for STER limited to the submucosal and/or muscularis propria layer
* Aged 18 years or older
Exclusion Criteria:
* Age less than 18
* Unable to give informed consent
* Pregnant or lactating patients
* Patients with bleeding diathesis or who cannot discontinue ADP blockers (e.g. clopidogrel, prasugrel) or antithrombotics (e.g. warfarin, dabigatran) periprocedurally
Primary outcome measure(s)
Effectiveness of endoscopic resection of UGI neoplastic lesions: completeness of resection — 2 weeks Determined based on clear margins in histology review
Safety: intra and post procedural; bleeding; perforation; anaesthetic — 30 day Intraprocedural bleeding, clinically significant post-polypectomy bleeding, deep mural injury, post polypectomy coagulation syndrome
Long term outcomes: recurrent and residual disease — 3 years Determined at subsequent procedures
Trial sites (1)
Facility
City
Region
Status
Westmead Hospital
Sydney
New South Wales
Recruiting
More Western Sydney Local Health District trials in Australia
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
